Accord trial fenofibrate

J Clin Endocrinol Metab. Diabetes Care. Epub Nov 3. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. Epub Jul Epub Mar Waist circumference is associated with major adverse cardiovascular events in male but not female patients with type-2 diabetes mellitus. Association of predicted lean body mass and fat mass with cardiovascular events in patients with type 2 diabetes mellitus.

Epub Sep Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. J Clin Hypertens Greenwich. Epub May 7. Circ Cardiovasc Qual Outcomes. Am J Hypertens. J Am Heart Assoc. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol.

Epub Dec 6. Epub Nov Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus. J Hypertens. JAMA Cardiol. Epub Jun Am J Nephrol. Nine-Year Effects of 3. Epub Jan Epub Oct Diabet Med. Epub Sep 6. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Epub Feb 9. Epub Feb 5. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.

Kidney Int. Epub Sep 5. Epub Aug Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus from the Action to Control Cardiovascular Risk in Diabetes Study.

J Gen Intern Med. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Epub Mar 4.

Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. Epub Dec 2. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Epub Feb Epub Dec Epub Oct 1. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data.

BMC Endocr Disord. Epub May Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Genuth S, Ismail-Beigi F. Epub Nov 2. Reprints and Permissions. Small triumph for fenofibrate therapy in dyslipidaemia.

Nat Rev Cardiol 14, — Download citation. Published : 02 February Issue Date : March Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.

Advanced search. Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Skip to main content Thank you for visiting nature. Subjects Drug therapy Dyslipidaemias Type 2 diabetes. Access through your institution. Buy or subscribe. This is a preview of subscription content. Change institution. Buy article Get time limited or full article access on ReadCube. References 1 Collins, R. Author information Affiliations Robert S.

Rosenson Authors Robert S. In addition, participants were enrolled in either the blood pressure trial or the lipid trial and were treated and followed for an average of about five years. The ACCORD blood pressure trial is the largest clinical trial to test the effect on cardiovascular disease of systolic blood pressure the top number in a blood pressure reading below mmHg, which is considered normal.

Current blood pressure guidelines recommend that adults with type 2 diabetes maintain systolic blood pressure at less than mm Hg. Previous clinical trials have only proven benefits to less than mm Hg; however, observational studies have linked systolic blood pressure levels of mmHg or below to lower cardiovascular disease rates in adults with type 2 diabetes.

A clinical trial was needed to determine the effects of treatment to reach this normal systolic blood pressure level in these patients. Researchers randomly assigned 4, participants with elevated blood pressure to a target systolic blood pressure of either less than mmHg the intensive group or to less than mmHg the standard group.

A variety of FDA-approved blood pressure medications was used to reach blood pressure goals. After an average follow-up of about five years, researchers found no significant differences between the intensive group and the standard group in rates of a combined endpoint including nonfatal heart attack, nonfatal stroke, or cardiovascular death. There were cardiovascular events in the intensive group and events in the standard group.

Lowering blood pressure to below the standard level significantly cut the risk of stroke by about 40 percent. The intensive blood pressure group had 36 strokes, compared to 62 strokes in the standard group.

The researchers caution, however, that participants in the intensive blood pressure group were more likely to have complications such as abnormally low blood pressure or high levels of blood potassium. They noted 77 events in the intensive groups compared to 30 in the standard group. In addition, some laboratory measures of kidney function were worse in the intensive therapy group, but there was no difference in the rates of kidney failure.

Cushman, M. This finding is consistent with other blood pressure trials. The ACCORD lipid trial studied whether adding a fibrate to a statin to improve multiple blood lipids is more effective at lowering the risk of cardiovascular events than treatment with a statin alone.

Both statins and fibrates are commonly used medications to treat abnormal levels of blood lipids. Statins lower LDL, or bad cholesterol, and are proven to lower cardiovascular disease risk in people with diabetes. Fibrates primarily lower fats in the blood known as triglycerides and raise HDL or good cholesterol.

Fibrates are sometimes used in combination with statins. High triglycerides and low HDL levels are common in diabetes patients.